Zobrazeno 1 - 10
of 36
pro vyhledávání: '"G L Drusano"'
Autor:
G. L. Drusano
Publikováno v:
European Respiratory Review, Vol 16, Iss 103, Pp 45-49 (2007)
Rational therapy of ventilator-associated pneumonia requires choosing the right drug at the right dose. The choice of dose depends on the microbiological goal, the range of minimum inhibitory concentrations (MICs) for likely pathogens, the extent of
Externí odkaz:
https://doaj.org/article/b58b34a9655642cfa1137564d4d479ce
Autor:
G L, Drusano, Robert A, Bonomo, Steven M, Marshall, Laura J, Rojas, Mark D, Adams, Maria F, Mojica, Barry N, Kreiswirth, Liang, Chen, Nino, Mtchedlidze, Meredith, Bacci, Michael, Vicchiarelli, Jürgen B, Bulitta, Arnold, Louie
Publikováno v:
Antimicrob Agents Chemother
Ceftazidime (CAZ)-avibactam (AVI) is a β-lactam/β-lactamase inhibitor combination with activity against type A and type C β-lactamases. Resistance emergence has been seen, with multiple mechanisms accounting for the resistance. We performed four e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::30ef4a56187fbdc72c10eed98671131c
https://pubmed.ncbi.nlm.nih.gov/33782013
https://pubmed.ncbi.nlm.nih.gov/33782013
Publikováno v:
mBio, Vol 2, Iss 4 (2011)
ABSTRACT Some trials administered antituberculosis agents for 5 of 7 days (5/7-day regimen) to optimize adherence. Since moxifloxacin has a longer half-life than rifampin, rifampin concentrations are 2 log10 CFU/ml above the low-exposure 7/7-day arm.
Externí odkaz:
https://doaj.org/article/1c54c34996e94dfda6cdb8f76184fbad
Publikováno v:
mBio, Vol 1, Iss 3 (2010)
ABSTRACT Moxifloxacin is under development for expanded use against Mycobacterium tuberculosis. Rifampin is a mainstay of therapy. We examined the interaction of moxifloxacin plus rifampin for log-phase and nonreplicating persister (NRP) organisms. F
Externí odkaz:
https://doaj.org/article/346a155c92eb441da601c67a03e408da
Autor:
G L, Drusano, Ryan K, Shields, Nino, Mtchedlidze, M Hong, Nguyen, Cornelius J, Clancy, Michael, Vicciarelli, Arnold, Louie
Publikováno v:
Antimicrobial agents and chemotherapy. 63(8)
Ceftazidime-avibactam (CAZ/AVI) combines ceftazidime with a diazabicyclooctane non-β-lactam β-lactamase inhibitor. This has potent inhibitory activity against KPC-type enzymes. We studied activity of clinically relevant regimens of CAZ/AVI against
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d1b4d590ba88fdaffe113195156d3f62
https://pubmed.ncbi.nlm.nih.gov/31160285
https://pubmed.ncbi.nlm.nih.gov/31160285
Autor:
G. M. Eliopoulos, G. L. Drusano, P. G. Ambrose, S. M. Bhavnani, J. S. Bertino, A. N. Nafziger, A. Louie
Publikováno v:
Clinical Infectious Diseases. 45:753-760
Gram-negative organisms have become increasingly resistant to both b-lactam antibiotics and fluoroquinolones. Consequently, aminoglycoside antibiotics have undergone a resurgence in use. Because of the known toxicities of aminoglycoside antibiotics,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eebdaea1f13776d1ba625762bfbf0701
https://doi.org/10.1086/520991
https://doi.org/10.1086/520991
Autor:
G. L. Drusano
Publikováno v:
European Respiratory Review. 16:45-49
Rational therapy of ventilator-associated pneumonia requires choosing the right drug at the right dose. The choice of dose depends on the microbiological goal, the range of minimum inhibitory concentrations (MICs) for likely pathogens, the extent of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4af60d8e3d12f3efe8d19ac2211954a
https://doi.org/10.1183/09059180.00010304
https://doi.org/10.1183/09059180.00010304
Autor:
G L Drusano
Publikováno v:
Journal of Chemotherapy. 12:21-26
By using mathematical modeling it is possible to determine relationships between drug exposure and clinical or microbiological outcome. From the early exploration of Pseudomonas aeruginosa sepsis in neutropenic rats to the prospective determination o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cc1a8d07b2e239075ed64ffb8eae708
https://doi.org/10.1080/1120009x.2000.11782309
https://doi.org/10.1080/1120009x.2000.11782309
Publikováno v:
Antimicrobial Agents and Chemotherapy. 37:483-490
We examined the impact of dose fractionation and altered MICs on survivorship in a neutropenic rat model of Pseudomonas aeruginosa sepsis employing the new fluoroquinolone antibiotic lomefloxacin. Once-daily administration of a drug dose which produc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8767c7a5935ff228fc04d592d467c8f
https://doi.org/10.1128/aac.37.3.483
https://doi.org/10.1128/aac.37.3.483
Autor:
G. L. Drusano
Publikováno v:
Antimicrobial Drug Resistance ISBN: 9781603275927
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ad84849b469a4b1652276f78876db5c
https://doi.org/10.1007/978-1-59745-180-2_3
https://doi.org/10.1007/978-1-59745-180-2_3
